| Date | Title | Description |
| 03.06.2025 | Dimension Bio Appoints Biotech Veteran Heidi Hagen to Board of Directors | Heidi Hagen
Dimension Bio appoints biotechnology veteran Heidi Hagen to its Board of Directors, bringing decades of cell therapy leadership as the company advances its liver failure program toward the clinic.
CHICAGO, June 3, 2025 /PRNewswi... |
| 25.07.2023 | A-Alpha Bio Secures $22.4M Series A2 Round |
SEATTLE, WA, A-Alpha Bio, a synthetic biology and machine learning (ML) company that measures and engineers protein-protein interactions, today announced a $22.4 million Series A2.
>> Click here for more funding data on A-Alpha Bio... |
| 25.07.2023 | A-Alpha Bio, a biotech startup that measures and predicts protein interactions, raises $22.4M | The A-Alpha Bio team. The Seattle startup generates protein interaction data and partners with drug companies to help them find the best agents to test on a range of conditions. (A-Alpha Bio Photo)
Seattle biotech startup A-Alpha Bio raised... |
| 25.07.2023 | A-Alpha Bio Raises $22.4M in Series A2 Funding | A-Alpha Bio, a Seattle, WA-based synthetic biology and machine learning (ML) company that measures and engineers protein-protein interactions, raised $22.4M in Series A2 funding.
The round, which brought the total amount to total funding to... |
| 25.07.2023 | A-Alpha Bio Raises $22.4M in Series A2 to Scale Protein-Protein Interaction Data Platforms and Accelerate Internal Pipeline Development | A-Alpha Bio Their platforms have already shown a great deal of promise through their internal pipeline and partnerships, and we believe they have the potential to redefine our understanding of protein-protein interactions and accelerate the... |
| 05.07.2023 | A-Alpha Bio Announces Collaboration With Gilead to Advance Next-Generation HIV Therapeutic Options | A-Alpha Bio, a synthetic biology and machine learning company that measures and engineers protein-protein interactions announced a collaboration with Gilead Sciences, Inc. (Gilead) that aims to advance the design of human immunodeficiency v... |
| 27.06.2023 | A-Alpha Bio Welcomes Heidi Hagen to Its Board of Directors | A-Alpha Bio Her extensive experience as a biotechnology leader, founder, and operator will be instrumental in successfully developing our platforms, progressing our pipeline, and advancing A-Alpha Bio's mission to improve human health by me... |
| 13.06.2023 | A-Alpha Bio Announces Collaboration With Gilead to Advance Next-Generation HIV Therapeutic Options | We are excited to collaborate with Gilead to advance the next generation of HIV therapies, drawing on our expertise in discovering and optimizing highly cross-reactive biologics
SEATTLE (PRWEB) June 13, 2023
A-Alpha Bio, a synthetic biology... |
| 16.05.2023 | A-Alpha Bio and Lawrence Livermore National Laboratory expand collaboration to accelerate antibody discovery and development for biothreats | A-Alpha Bio “Our collaboration with the A-Alpha Bio team leverages their platform and expertise toward state-of-the-art computational models that will accelerate drug discovery.”
SEATTLE (PRWEB) May 16, 2023
A-Alpha Bio, a synthetic biology... |
| 20.10.2022 | Life sciences entrepreneurs offer advice on launching and building startups | Clockwise from top left: A-Alpha Bio CEO David Younger; UW Medicine surgeon Christopher Allan; Apertur CEO Robin Alfieri; Anavasi Diagnostics co-founder Barry Lutz; former PvP Biologics CEO Ingrid Swanson Pultz. (A-Alpha Bio and UW Photos)
... |
| 23.08.2022 | A-Alpha Bio Announces Collaboration with Bristol Myers Squibb to Discover Molecular Glue Targets for Protein Degradation | A-Alpha will identify and characterize novel pairs of E3 ubiquitin ligases and targets that Bristol Myers Squibb will utilize for potential design and development of molecular glues to induce targeted protein degradation.
SEATTLE (PRWEB) Au... |
| 01.03.2022 | A-Alpha Bio and Lawrence Livermore National Laboratory collaborate to accelerate therapeutic antibody discovery against emerging COVID-19 variants | A-Alpha Bio and Lawrence Livermore National Laboratory (LLNL), today announced a collaboration to accelerate therapeutic antibody discovery against emerging COVID-19 variants using synthetic biology and machine learning.
SEATTLE (PRWEB) Mar... |
| 16.12.2021 | A-Alpha Bio Partners with Kymera Therapeutics to Discover Novel Interactions for Molecular Glue Discovery | “Kymera and A-Alpha share a commitment to innovation and to expanding the potential of targeted protein degradation by unlocking new ligases and new previously undruggable targets." -David Younger, PhD, Co-Founder and CEO of A-Alpha Bi... |
| 30.11.2021 | Padma Kodukula Joins A-Alpha Bio as Chief Business Officer | “We have an ambitious mission, proven technology, and a desire to leave healthcare a better place than we found it. We’re proud to welcome Padma, and I look forward to closely working alongside her as we aggressively expand our business.” -... |
| 13.09.2021 | Digital health news, funding roundup in the prior week; September 13 | Beauty Pie raised $100 million; Homage landed $30M; DotCom Therapy picked up $13M
Cleveland Clinic: Cleveland Clinic is an Ohio-based medical center that combines clinical and hospital care with research and education. Anthem is teaming up ... |
| 10.09.2021 | Daily funding roundup - September 10th, 2021 | Vouch raised $90M; Flo landed $50M; A-Alpha Bio secured $20M
Agile Robots: Agile Robots is a Munich, Germany-based robotics startup that spun out of the German Aerospace Center. Agile Robots has raised $220 million in Series C funding. Soft... |
| 09.09.2021 | What Andreessen Horowitz’s recent hiring surge says about the venture capital investor | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
Paid Content 4 ways CEOs can build a successful cloud strategy From PWC
Andreessen Horowitz has m... |
| 09.09.2021 | What Andreessen Horowitz’s recent hiring surge says about the venture capital investor | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
Andreessen Horowitz has made itself into a premier venture capital investing shop on Sand Hill Ro... |
| 08.09.2021 | A-Alpha Bio Snares $20M Series A Funding |
SEATTLE, WA, A-Alpha Bio, a biotechnology company, announced a $20M Series A funding led by Madrona Venture Group.
>> Click here for more funding data on A-Alpha Bio
>> To export A-Alpha Bio funding data to PDF and Excel, cl... |
| 08.09.2021 | A-Alpha Bio Secures $20M Series A Financing to Accelerate Drug Discovery by Measuring Protein-Protein Interactions at Scale | When it comes to measuring protein-protein interactions and assisting pharma in the discovery of antibodies and molecular-glue targets, A-Alpha Bio's AlphaSeq platform is unmatched. AlphaSeq is enabling pharma companies to find the high-val... |
| 08.09.2021 | University of Washington spinout A-Alpha Bio snags $20M for protein-discovery platform | A-Alpha Bio founders David Younger (standing) and Randolph Lopez. (A-Alpha Bio Photo).
A-Alpha Bio will build lab space in downtown Seattle and beef up its machine learning team with $20 million in new venture funding for its operation to i... |
| 07.09.2021 | Via Nova Therapeutics Announces $20 Million Series A Financing from Aditum Bio to Advance Four Antiviral Programs | |
| 27.09.2019 | A-Alpha Bio Closes a $2.8M Seed Round |
SEATTLE, WA, A-Alpha Bio has raised $2.8M from leading science-focused venture capital firms and angel investors.
>> Click here for more funding data on A-Alpha Bio
>> To export A-Alpha Bio funding data to PDF and Excel, cli... |
| 24.09.2019 | A-Alpha Bio raises $2.8M for genetically engineered drug discovery platform | The A-Alpha Bio team includes scientist Emily Engelhart, principal scientist David Colby, co-founder and CEO David Younger, co-founder and chief technology officer Randolph Lopez and engineering associate Charles Lin. (A-Alpha Bio Photo)
A ... |
| 24.09.2019 | A-Alpha Bio Closes $2.8M Seed Funding | A-Alpha Bio, a Seattle, WA-based biotechnology startup for pharmaceutical companies to characterize protein interactions for accelerated drug development, raised $2.8M in funding.
The round was led by OS Fund and also includes AME Cloud Ven... |
| 24.07.2018 | Clinical drug screening startup A-Alpha Bio awarded Small Business Innovation Research grant | A-Alpha Bio CEO David Younger (left) and CTO CTO Randolph Lopez (right) in the startup’s new lab, in the University of Washington’s Fluke Hall. (Photo courtesy of A-Alpha Bio)
A-Alpha Bio, a startup aiming to speed up the development of new... |
| 25.05.2018 | Pre-clinical drug screening startup A-Alpha Bio wins first place at Univ. of Washington Business Plan Competition | The A-Alpha Bio team, from left to right: David Younger, Bob Lamm, Matt Johnson, Randolph Lopez. (GeekWire photo / Taylor Soper)
Pharmaceutical companies spend a lot of money and time developing new drugs. Now a new startup created by a gro... |
| 06.07.2017 | DDF Invests in $20 Million in Series A Funding of Mitoconix Bio to Develop Neurodegenerative Disease Therapies | Ness Ziona, Israel June 27, 2017 - Mitoconix Bio Ltd., a biopharmaceutical company focused on therapies for neurological diseases, announced today that it has secured a $20 million round of Series A funding. The round was led by Remiges Ven... |
| - | A-Alpha Bio | “Measure more protein interactions” |
| - | 9 top West Coast biotechs that VCs say are poised to take off in the next year | Tayfun Coskun/Anadolu Agency/Getty Images This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Insider asked 12 venture capitalists which biotech startups would take off in the next 12 months.... |
| - | Meet the 23 biotech startups that are set to take off in the next 12 months, according to top VCs | Tyler Le/Insider This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Insider asked 12 venture capitalists which biotech startups would take off in the next 12 months.
Here are the 23 companie... |
